A peptide vaccine targeting angiotensin II attenuates the cardiac dysfunction induced by myocardial infarction

  title={A peptide vaccine targeting angiotensin II attenuates the cardiac dysfunction induced by myocardial infarction},
  author={Ryo Watanabe and Jun-Ichi Suzuki and Kouji Wakayama and Yasuhiro Maejima and Munehisa Shimamura and Hiroshi Koriyama and Hironori Nakagami and Hidetoshi Kumagai and Yuichi Ikeda and Hiroshi Akazawa and Ryuichi Morishita and Issei Komuro and Mitsuaki Isobe},
  journal={Scientific Reports},
A peptide vaccine targeting angiotensin II (Ang II) was recently developed as a novel treatment for hypertension to resolve the problem of noncompliance with pharmacotherapy. Ang II plays a crucial role in the pathogenesis of cardiac remodeling after myocardial infarction (MI), which causes heart failure. In the present study, we examined whether the Ang II vaccine is effective in preventing heart failure. The injection of the Ang II vaccine in a rat model of MI attenuated cardiac dysfunction… 

Prevention of Progression of Aortic Aneurysm by Peptide Vaccine Against Ang II (Angiotensin II) in a Rat Model

Four weeks after operation, the increase in Ang II in the aneurysm wall was significantly inhibited by treatment with Ang II vaccine, suggesting this vaccine therapy could become a potent therapeutic option to treat patients with AAA.

A novel soluble epoxide hydrolase vaccine protects murine cardiac muscle against myocardial infarction

A new vaccine to inactivate soluble epoxide hydrolase to prolong the activation of epoxyeicosatrienoic acids, which have vasodilatory and anti-inflammatory properties is made and evaluated in a rat myocardial infarction model.

Therapeutic Vaccines for Hypertension: a New Option for Clinical Practice

The concept of therapeutic vaccines for hypertension and future directions for therapeutic vaccines are described and increased the effectiveness of drug adherence interventions in the clinical setting may have a large impact on the health of the population.

The ATRQβ-001 vaccine improves cardiac function and prevents postinfarction cardiac remodeling in mice

The ATRQβ-001 vaccine decreased mortality and improved cardiac function and remodeling after acute myocardial infarction, and significantly inhibited the TGF-β1/Smad2/3 signaling pathway.

Vaccine Development against the Renin-Angiotensin System for the Treatment of Hypertension

The history of the development of immunotherapies for the treatment of hypertension is reviewed, a human clinical trial that indicated the effectiveness and safety of a virus-like particle-based antiangiotensin II vaccine marked a turning point in the field of therapeutic antihypertensive vaccines.

Vaccines against components of the renin–angiotensin system

The different vaccination attempts with proteins and peptides against the different molecules of the renin–angiotensin system in the last two decades are reviewed, safety issues, and other novel prospects biomarkers in hypertension are summarized, and the potential of this immunomodulatory approach in clinical practice is summarized.

Protective effects of Xinji′erkang on myocardial infarction induced cardiac injury in mice

Xinji′erkang exerts cardioprotective effect on myocardial infarction in mice, which may be due to the improvement of endothelial dysfunction and the reduction of oxidative stress and inflammation response.

Future Directions of Therapeutic Vaccines for Chronic Diseases.

An original B-cell vaccine to induce antibody production and used carrier proteins, which include exogenous T-cell epitopes through the major histocompatibility complex are introduced and the therapeutic potential for cardiovascular diseases is described.



Telmisartan, a unique ARB, improves left ventricular remodeling of infarcted heart by activating PPAR gamma

In conclusion, Telmisartan prevented unfavorable cardiac remodeling through a reduction of cardiac hypertrophy and fibrosis through an anti-inflammatory effect and PPAR-γ activation were suggested to be important in addition to suppression of Ang II activity.

Impaired post-infarction cardiac remodeling in chronic kidney disease is due to excessive renin release

The data suggest that renal disorder results in ventricular dysfunction and deteriorates remodeling after MI through excessive RAS activation, and renin inhibition improved the changes caused by cardiorenal syndrome.

Inhibition of NF-{kappa}B improves left ventricular remodeling and cardiac dysfunction after myocardial infarction.

In conclusion, inhibition of NF-kappaB activation may reduce the proinflammatory reactions and modulate the extracellular matrix and provide an effective approach to prevent adverse cardiac remodeling after MI.

Effects of angiotensin II receptor blockade versus angiotensin-converting-enzyme inhibition on ventricular remodelling following myocardial infarction in the mouse.

In this model, AT(1) receptor antagonism and ACE inhibition have equivalent inhibitory effects on myocardial hypertrophy and fibrosis, and serve as an important basis for planned investigations to evaluate the anti-remodelling effects of these agents on mice in which genetic manipulations are used to disrupt components of the Ang II signalling system.

Peptide Vaccines for Hypertension and Diabetes Mellitus

The system was used to design a therapeutic vaccine that elicits anti-Ang II or DPP4 antibodies without CTL activation against Ang II orDPP4, and this concept of therapeutic vaccines for hypertension and diabetes mellitus is described.

A Comparison Between Imidapril and Ramipril on Attenuation of Ventricular Remodeling After Myocardial Infarction

Imidapril had a superior effect for preventing ventricular remodeling characterized by fibrosis and collagen accumulation in left ventricle compared with ramipril in the moderate and large MI groups, even though the dosage used in this study was too small to reduce systemic blood pressure.

Vaccine for hypertension: modulating the renin-angiotensin system.